VIVEX BIOLOGICS

Issues related to coverage of and reimbursement for Human Cell & Tissue products. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.

Client expense: — · Firm income: $50,000

Matched citations: H.R.6852

Issues related to coverage of and reimbursement for Human Cell & Tissue products. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.

Client expense: — · Firm income: $50,000

Matched citations: S. 2561

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.

Client expense: — · Firm income: $50,000

Matched citations: H.R. 5768

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.

Client expense: — · Firm income: $50,000

Matched citations: H.R.6852

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F) Skin Substitute Access and Payment Reform Act of 2025 (H.R. 5768/S. 2561). H.R.6852 - To amend title XVIII of the Social Security Act to adjust payment for skin substitute products under the Medicare program.

Client expense: — · Firm income: $50,000

Matched citations: S. 2561

Issues related to coverage of and reimbursement for Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain. Issues related to skin substitute payment in 2026 Physician Fee Schedule Proposed Rule (CMS-1832-P). Skin Substitute Access and Payment Reform Act of 2025 (S. 2561)

Client expense: — · Firm income: $50,000

Matched citations: S. 2561

H.R.7188/S.3733 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)

Client expense: — · Firm income: $50,000

Matched citations: H.R.6705

H.R.7188/S.3733 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)

Client expense: — · Firm income: $50,000

Matched citations: H.R.7188

H.R.7188/S.3733 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)

Client expense: — · Firm income: $50,000

Matched citations: S.3733

H.R.7188 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)

Client expense: — · Firm income: $50,000

Matched citations: H.R.6705

H.R.7188 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)

Client expense: — · Firm income: $50,000

Matched citations: H.R.7188

H.R.7188 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)

Client expense: — · Firm income: $50,000

Matched citations: H.R.6705

H.R.7188 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Education on Human Cellular Tissue Products (HCTPs)

Client expense: — · Firm income: $50,000

Matched citations: H.R.7188

H.R.7188 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Issues related to Human Cellular Tissue Products (HCTP)

Client expense: — · Firm income: $20,000

Matched citations: H.R.6705

H.R.7188 - Shandra Eisenga Human Cell and Tissue Product Safety Act H.R.6705 - Effective Screening and Testing for Tuberculosis Act Issues related to Human Cellular Tissue Products (HCTP)

Client expense: — · Firm income: $20,000

Matched citations: H.R.7188

Issues related to HCT/P legislation (e.g. HR 7188/S. 3733)

Client expense: — · Firm income: —

Matched citations: HR 7188

Issues related to HCT/P legislation (e.g. HR 7188/S. 3733)

Client expense: — · Firm income: —

Matched citations: S. 3733